GlassScriptPhysician profile
Gabriel Chong
NPI 1578695862
$4,797.99
in general payments reported to CMS, 2019-2025
22 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $738 · 2021: $1,338 · 2022: $443 · 2023: $320 · 2024: $492 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Education: $23.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.71 |
| Education | $23.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $995.25 | 2019-2021 | |
| Alcon Vision LLC | $906.44 | 2019-2025 | Hydrus Microstent, Rocklatan, Lensx |
| Bausch & Lomb Americas INC. | $593.36 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $543.64 | 2019-2021 | |
| Glaukos Corporation | $377.09 | 2020-2025 | Photrexa Cross-Linking Kit, Idosetr |
| Novartis Pharmaceuticals Corporation | $264.44 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $256.31 | 2019-2021 | |
| Abbvie INC. | $210.25 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $154.43 | 2019-2021 | |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Harrow Eye, LLC | $74.26 | 2025 | Vevye |
| Amgen INC. | $52.79 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $46.65 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $41.69 | 2019-2021 | |
| Thea Pharma INC. | $36.88 | 2023-2025 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $30.77 | 2020 | |
| Horizon Therapeutics Plc | $29.74 | 2021-2022 | |
| Merz North America, INC. | $25.82 | 2020 | |
| Shire North American Group INC | $20.67 | 2019 | |
| Akorn Operating Company LLC | $19.11 | 2021 | |
| New World Medical,INC. | $18.16 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.